---
title: Amivantamab plus Chemotherapy in NSCLC with <em>EGFR</em> Exon 20 Insertions
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37870976/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231024180819&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: The use of amivantamab-chemotherapy resulted in superior
  efficacy as compared with chemotherapy alone as first-line treatment of patients
  with advanced NSCLC with EGFR exon 20 insertions. (Funded by Janssen Research and
  Development; PAPILLON ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: The use of amivantamab-chemotherapy resulted in superior efficacy as compared with chemotherapy alone as first-line treatment of patients with advanced NSCLC with EGFR exon 20 insertions. (Funded by Janssen Research and Development; PAPILLON ClinicalTrials.gov number, ...